SGEN NASDAQ
Seagen Inc.
1W: +0.0%
1M: +7.3%
3M: +6.1%
1Y: +72.9%
3Y: +15.6%
5Y: +321.2%
$228.74
Last traded 2023-12-22 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships0
As Filer
counterparties named
5
As Counterparty
mentioned by others
2021-03-25
Earliest Filing
2023-12-14
Latest Filing
Mentioned As Counterparty
5 mentionsOther companies that named SGEN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| PFE PFIZER INC | acquirer | Target company in the merger with Pfizer Inc. | 2023-12-14 | View |
| NRIX Nurix Therapeutics, Inc. | partner | Entered into a Collaboration and License Agreement for developing targeted protein degraders and Degrader-Antibody Conju | 2023-09-07 | View |
| PFE PFIZER INC | acquirer | Target company in a merger agreement with Pfizer Inc. | 2023-03-13 | View |
| ZLAB Zai Lab Ltd | partner | Collaboration and license agreement for TIVDAK® development and commercialization in mainland China, Hong Kong, Macau, a | 2022-09-27 | View |
| PVLA PIERIS PHARMACEUTICALS, INC. | investor | Strategic equity investment and collaboration for combination study of cinrebafusp alfa and TUKYSA | 2021-03-25 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR